Novavax, Inc. (NVAX) Announces Positive Top-Line Results From Phase 1 Clinical Trial of RSV Vaccine Candidate in Elderly
7/2/2013 8:02:29 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ROCKVILLE, Md., July 2, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced positive top-line safety and immunogenicity data for its respiratory syncytial virus (RSV) vaccine candidate from a dose-ranging Phase 1 study in elderly adults. All subject groups receiving the recombinant fusion (F) protein nanoparticle vaccine candidate exhibited antibody responses against RSV at 28 and 56 days post-immunization, with rises in serum anti-F immunoglobulin G (IgG) antibody levels. The highest response rates and greatest increases in antibody levels were observed in groups receiving RSV F antigen with aluminum phosphate as an adjuvant. All subjects simultaneously received a licensed seasonal trivalent influenza vaccine to ensure coverage over the influenza season. Local and systemic safety were monitored and together with the interim immunogenicity are provided here as top line data through Day 56.
Help employers find you! Check out all the jobs and post your resume.
comments powered by